CHEBI:51137 - mianserin

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name mianserin
ChEBI ID CHEBI:51137
Definition A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C18H20N2
Net Charge 0
Average Mass 264.36480
Monoisotopic Mass 264.16265
InChI InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
InChIKey UEQUQVLFIPOEMF-UHFFFAOYSA-N
SMILES CN1CCN2C(C1)c1ccccc1Cc1ccccc21
Roles Classification
Biological Role(s): alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
adrenergic uptake inhibitor
Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
histamine agonist
A drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
Application(s): antidepressant
Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
sedative
A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
adrenergic uptake inhibitor
Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
histamine agonist
A drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically.
H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
geroprotector
Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing mianserin (CHEBI:51137) has role α-adrenergic antagonist (CHEBI:37890)
mianserin (CHEBI:51137) has role adrenergic uptake inhibitor (CHEBI:35640)
mianserin (CHEBI:51137) has role antidepressant (CHEBI:35469)
mianserin (CHEBI:51137) has role EC 3.4.21.26 (prolyl oligopeptidase) inhibitor (CHEBI:76779)
mianserin (CHEBI:51137) has role geroprotector (CHEBI:176497)
mianserin (CHEBI:51137) has role H1-receptor antagonist (CHEBI:37955)
mianserin (CHEBI:51137) has role histamine agonist (CHEBI:35678)
mianserin (CHEBI:51137) has role sedative (CHEBI:35717)
mianserin (CHEBI:51137) has role serotonergic antagonist (CHEBI:48279)
mianserin (CHEBI:51137) is a dibenzoazepine (CHEBI:47804)
Incoming mianserin hydrochloride (CHEBI:31843) has part mianserin (CHEBI:51137)
IUPAC Name
2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
INNs Sources
mianserin WHO MedNet
mianserina WHO MedNet
miansérine WHO MedNet
mianserinum WHO MedNet
Synonym Source
1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine ChemIDplus
Manual Xrefs Databases
1796 DrugCentral
DB06148 DrugBank
LSM-1374 LINCS
Mianserin Wikipedia
NL6603256 Patent
US3534041 Patent
View more database links
Registry Numbers Types Sources
24219-97-4 CAS Registry Number ChemIDplus
755346 Beilstein Registry Number Beilstein
Citations Waiting for Citations Types Sources
18033297 PubMed citation Europe PMC
20825390 PubMed citation Europe PMC
Last Modified
26 October 2021